糖尿病足患者血小板相关参数的变化及抗血小板聚集治疗  

Study on the Changes of the Platelet Parameters and the Clinical Significance of Anti-platelet Therapy in Diabetes Foot

作　　者：曹凤林[1] 郭剑超[1] 王艳萍[1] 李玉红[1] 王君[1] 王洋[1] 李福旺[1] 郑少雄[1] 

机构地区：[1]天津医科大学第二医院血液内分泌科,300211

出　　处：《天津医药》2006年第12期856-857,共2页Tianjin Medical Journal

摘　　要：目的:分析糖尿病足患者平均血小板体积和数量变化的临床意义,同时探讨抗血小板聚集治疗在糖尿病足治疗中的作用。方法:分别测定48例2型糖尿病足患者(糖尿病足组)和30例同龄2型糖尿病无并发症患者(糖尿病组)以及30例健康同龄人(对照组)的平均血小板体积(MPV)、血小板数量(BPC),观察西洛他唑治疗前后12例糖尿病足患者上述参数的变化。结果:糖尿病足组MPV比正常对照组和糖尿病组增大(均P<0.01),BPC比正常对照组和糖尿病组减少(均P<0.01);而正常对照组和糖尿病组之间MPV和BPC差异均无统计学意义(均P>0.05)。12例糖尿病足患者经西洛他唑治疗后BPC较治疗前明显升高(P<0.01),MPV与治疗前相比差异无统计学意义(P>0.05)。结论:糖尿病足除了感染、血管和神经的因素外,血小板在糖尿病足的发病过程也起了重要作用,抗血小板聚集治疗是糖尿病足治疗中的重要措施。Objective： To study the changes of the platelet parameters and the clinical significance of anti-platelet therapy in diabetes foot. Methods： The mean platelet volume （MPV） and the blood platelet count （BPC） were determined in 48 patients with diabetes foot, 30 type 2 diabetes with no complication and 30 normal controls. MPV and BPC were observed before and after cilostazol administration in 12 diabetes foot. Results： The MPV of diabetes foot group was higher than those of type 2 diabetes with no complication group and normal control group （P 〈 0.01）. The BPC of diabetes foot group was lower than those of other two groups （P 〈 0.01）. There were no significant differences in BPC and MPV between diabetes patients with no complication group and normal control group （P 〉 0.05）. The BPC increased significantly after cilestazol therapy in 12 diabetes foot compared with that before therapy （P 〈 0.01） and there was no significant difference in MPV between before and after therapy （P 〉 0.05）. Conclusion： Besides infection, vascular and nervous factors, the platelet plays an important role in the course of diabetes foot, and anti-platelet therapy is an important method in diabetes foot.

关 键 词：糖尿病足 血小板计数 四唑类 磷酸二酯酶抑制剂 

分 类 号：R743.31[医药卫生—神经病学与精神病学]